Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

Spaulding Clinical Research Awarded Five-Year Contract With FDA


Spaulding Clinical Research today announced that it has been awarded a five-year contract with the U.S. Food and Drug Administration (FDA) Division of Applied Regulatory Science to conduct multiple clinical trials in various therapeutic areas of interest. They have kicked off this agreement with $5 million of clinical trial work to be run in 2020. Spaulding Clinical is responsible for conducting the trials and providing the necessary support services including clinical trial recruitment, conduct, and laboratory assessments.

The objectives of each trial vary considerably among different therapeutic areas, but all address important regulatory science questions in today's pharmaceutical market.

"We are happy to partner with the FDA to help address agency questions about various classes of drugs. Spaulding Clinical is perfectly suited to conduct these trials as we have the right-sized project management and principal investigator team that will be able to give the FDA office the attention they need," said Cassandra Erato, CEO at Spaulding Clinical Research.

Spaulding Clinical has been working with the U.S. government on clinical trials over the past seven years. "We began conducting clinical trials for the FDA to explore a model to screen new drugs for prolongation of QT. Through this work and resulting publications, we have developed a productive partnership," said Dr. Jay Mason, chief medical officer at Spaulding Clinical Research.

About Spaulding Clinical Research
Spaulding Clinical opened in 2008 and was built upon fully electronic data and integrated, purposefully engineered systems for conducting Phase 1 trials. Spaulding runs a 200-bed facility in West Bend, Wisconsin, and conducts and analyzes First-in-Human, clinical Proof-of-Concept, cardiovascular safety (TQT, concentration effect), and NDA-enabling clinical pharmacology studies. Spaulding Clinical provides expertise on study design, medical writing, clinical data management, biostatistics, and PK/PD analysis. Learn more at spauldingclinical.com.


These press releases may also interest you

at 08:15
TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has entered into a...

at 08:10
FirstWave Bio, Inc., a clinical-stage biotechnology company developing novel gut-targeted small molecules for inflammatory bowel disease and other serious conditions, today announced plans to initiate a Phase 2a/2b study in patients with COVID-19,...

at 08:10
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. and that the global licensing collaboration agreement with Biogen for the development and commercialization...

at 08:05
Merck , known as MSD outside the United States and Canada, announced today a commitment to strengthen health systems affected by the COVID-19 pandemic. Through Merck for Mothers, the company's global initiative to help end preventable maternal...

at 08:05
A new startup, i2O Therapeutics, has launched to commercialize innovations developed at Harvard University that may one day enable patients and clinicians to give up syringes in favor of pills. Using ionic liquid technologies developed in the lab...

at 08:05
X4 Pharmaceuticals, Inc. , a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the...



News published on 27 february 2020 at 08:05 and distributed by: